Editorial: PPIs and gastric cancer – Are we dealing with a carcinogen? Authors' reply

Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population‐based cohort study

(2023) Eun Jeong Gong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan

(2022) Yoshinobu Yamamoto et al.   JAMA Network Open

Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea

(2021) Seung In Seo et al.   GUT

Long-term proton pump inhibitors and risk of gastric cancer development after treatment forHelicobacter pylori: a population-based study

(2017) Ka Shing Cheung et al.   GUT

Proton-pump inhibitors: understanding the complications and risks

(2017) Peter Malfertheiner et al.   Nature Reviews Gastroenterology & Hepatology

Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology

(2015) L. Lundell et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Impact of Proton Pump Inhibitors on the Human Gastrointestinal Microbiome

(2014) Daniel E. Freedberg et al.   CLINICS IN LABORATORY MEDICINE